Cell Point

Cell>Point is a Centennial, CO-based, late-stage, phase 3 biotech company that excels in areas of theranostic nuclear medicine and chelation technologies. Cell Point, LLC, was established in 2001 after the leadership group licensed the University of Texas MD Anderson Cancer Center’s EC Technology Platform, then acquired four additional technology platforms, most of which are rooted in chelation chemistry. From these five platform technologies, Centennial, CO’s Cell>Point has identified more than 20 potential product opportunities related to the treatment of various diseases, several of which are already in active development.

Cell Point is best known for its lead product in clinical development, ethylenedicysteine-glucosamine, commercially known as Oncardia. Oncardia can fill various roles in the treatment of cardiovascular disease and cancer and has the capacity for both radiolabeling and complexing via cold metals, allowing for a diversity of nuclear imaging services and related therapeutic products. The flexibility of Oncardia allows for either technetium-99m imaging with SPECT camera systems or gallium-68 for imaging with PET systems. More information about Oncardia and other company services can be found online at www.Cellpointweb.com.